Emerging Innovations in Baculovirus Expression Vector System (BEVS): iBET Hosts iNOVA4Health Seminar by Dr. Imre Berger
“The MultiBac BEVS Platform in the Berger Lab: the Good, the Bad and the Ugly”
On November 10, iBET welcomed Dr. Imre Berger, Founding Director of the Max Planck Bristol Centre for Minimal Biology, Professor at the University of Bristol (UK), and European Research Council (ERC) Researcher, for a seminar on “The MultiBac BEVS Platform in the Berger Lab: the Good, the Bad and the Ugly”.
This talk offered a unique opportunity to explore the future of the Baculovirus Expression Vector System (BEVS). Traditionally used for recombinant protein production, BEVS is now evolving to meet the demands of next-generation biologics and therapeutic pipelines. Innovations presented by Dr. Berger position BEVS as a versatile platform for genome engineering, biologics manufacturing, and gene therapy, enabling applications in CRISPR gene editing, antiviral discovery, and snakebite research. Central to this progress is the MultiBac BEVS platform developed in his laboratory.
Dr. Berger created the MultiBac expression system, the snakebite vaccine platform – EU-Funded project ADDovenom, and contributed to identifying a druggable pocket in the SARS-CoV-2 spike protein. With nearly 200 peer-reviewed publications, multiple patents, and four biotech companies co-founded, his work has earned numerous honors, including the Swiss Technology Award and a Wellcome Trust Senior Investigator Award.
During this seminar the iNOVA4Health community had a glimpse into the future of BEVS as a next-generation vector platform, where its expanding role in global health and biotechnology was highlighted.
iBET extends its sincere thanks to Dr. Berger for sharing his expertise and delivering an inspiring seminar.
